U-Needle licenses Bella-mu to Aston sci.

U-Needle signs license and clinical supply agreement with Aston sci. for its Bella-mu intradermal delivery device

Enschede, The Netherlands, April 28th, 2021

U-Needle, a leading intradermal delivery technology company, announced today that it has signed a new license and clinical supply agreement with Aston sci. The agreement grants Aston sci. a non-exclusive license to U-Needle's intradermal delivery device, Bella-mu, for its application in selected Aston sci. programmes in oncology indications and additionally puts in place a multi-year clinical supply agreement.

“We are proud that Aston sci. selected our Bella-mu intradermal injection device for their clinical studies”, stated Jeroen Wissink, CEO of U-Needle. “After the approval of Bella-mu for the US and European markets, this agreement marks our first step into the Korean clinics.”

Dr. Hun Jung, CEO of Aston sci. said, “We are convinced that the Bella-mu device will make the administration of our product easy and reliable and thus improve the efficacy of our therapies under development.”


About Aston sci.:

Aston sci. Co., Ltd. is a Korea-based clinical stage biopharmaceutical company, established by the former members of multinational pharmaceutical companies. Aston sci. is highly regarded in the industry for its active pipelines and portfolio composition that mainly focuses on clinical development of innovative medicines in oncology, immunology, and geriatrics, including therapeutic cancer vaccines and proteostasis modulators. Most recently, Aston sci. announced that a therapeutic cancer vaccine called AST-021p was approved for the first-in-human study and another asset called AST-301 is currently under review by the MFDS(Ministry of Food and Drug Safety, Republic of Korea) for its IND application for the phase 2 clinical trials.


About U-Needle:

U-Needle has developed Bella-mu, a range of needles created for intradermal drug delivery. Intradermal injections are used for many innovative therapies and vaccines as well as for treatments in the field of aesthetics. Bella-mu is an easy-to-use, patient friendly intradermic needle that is very small (micro), very sharp, highly accurate and its use is far more reliable than conventional methods. Bella-mu is manufactured using semiconductor technology, making it a highly scalable product. Bella-mu is CE certified, has recently received FDA 510(k) clearance and is currently supplied globally to top tier pharma companies.